OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CLHO$6.6158

Cleopatra Hospital SAE

Healthcare Facilities & ServicesVerified

Cleopatra Hospital SAE has a liquidity ratio of 1.36, indicating a moderate level of liquidity. The company's price-to-book ratio is 3.93, which is relatively high, suggesting that the market is valuing the company's equity at a premium. The company's price-to-earnings ratio is 52.58, indicating that investors are willing to pay a high price for each dollar of earnings. In terms of profitability, Cleopatra Hospital SAE has a return on equity of 7.47% and a return on assets of 3.48%. These figures are to be compared against the industry's preferred metrics, which typically emphasize high returns on equity and assets. The company's operating income margin is 23.4%, and its net income margin is 15.4%, which are key indicators of its profitability. The company's revenue is primarily concentrated in its core hospital services, with no significant diversification into other segments. Geographically, the company's operations are centered in Egypt, and there is no indication of significant international expansion or diversification. Cleopatra Hospital SAE's growth trajectory is expected to be positive, with analysts providing a mean price target of 14.53 EGP, which is significantly higher than the current market price of 6.61 EGP. The company's revenue has shown a consistent growth pattern, and the positive analyst sentiment suggests a favorable outlook for the company's future performance. The company faces a medium level of liquidity risk, as indicated by the risk assessment. The key flag of negative net cash after subtracting total debt suggests that the company may need to manage its cash flow carefully. The dilution risk is assessed as low, and there are no significant adjustments applied to the company's valuations that would indicate a high dilution potential. Recent events and filings do not indicate any major changes or risks for Cleopatra Hospital SAE. The company's financial health appears stable, with a strong balance sheet and positive analyst recommendations. There are no recent transcripts or filings that suggest significant operational or financial challenges.

30-day price · CLHO+3.92 (+32.5%)
Low$11.93High$16.00Close$16.00As of14 May, 00:00 UTC
Profile
CompanyCleopatra Hospital SAE
TickerCLHO.CA
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Cleopatra Hospital SAE operates in the healthcare facilities and services industry, providing hospital services and generating revenue primarily through patient care and related healthcare services.

Classification. Cleopatra Hospital SAE is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a classification confidence of 0.92.

Cleopatra Hospital SAE has a liquidity ratio of 1.36, indicating a moderate level of liquidity. The company's price-to-book ratio is 3.93, which is relatively high, suggesting that the market is valuing the company's equity at a premium. The company's price-to-earnings ratio is 52.58, indicating that investors are willing to pay a high price for each dollar of earnings. In terms of profitability, Cleopatra Hospital SAE has a return on equity of 7.47% and a return on assets of 3.48%. These figures are to be compared against the industry's preferred metrics, which typically emphasize high returns on equity and assets. The company's operating income margin is 23.4%, and its net income margin is 15.4%, which are key indicators of its profitability. The company's revenue is primarily concentrated in its core hospital services, with no significant diversification into other segments. Geographically, the company's operations are centered in Egypt, and there is no indication of significant international expansion or diversification. Cleopatra Hospital SAE's growth trajectory is expected to be positive, with analysts providing a mean price target of 14.53 EGP, which is significantly higher than the current market price of 6.61 EGP. The company's revenue has shown a consistent growth pattern, and the positive analyst sentiment suggests a favorable outlook for the company's future performance. The company faces a medium level of liquidity risk, as indicated by the risk assessment. The key flag of negative net cash after subtracting total debt suggests that the company may need to manage its cash flow carefully. The dilution risk is assessed as low, and there are no significant adjustments applied to the company's valuations that would indicate a high dilution potential. Recent events and filings do not indicate any major changes or risks for Cleopatra Hospital SAE. The company's financial health appears stable, with a strong balance sheet and positive analyst recommendations. There are no recent transcripts or filings that suggest significant operational or financial challenges.
Key takeaways
  • Cleopatra Hospital SAE has a high price-to-book ratio, indicating a premium valuation of its equity.
  • The company's return on equity is 7.47%, which is a key indicator of its profitability.
  • Analysts have a positive outlook on the company, with a mean price target significantly higher than the current market price.
  • The company's liquidity ratio is moderate, suggesting a balanced approach to liquidity management.
  • The company's revenue is primarily concentrated in its core hospital services, with no significant diversification.
  • # RATIONALES
  • {
  • "margin_outlook_rationale": "The company's operating and net income margins are expected to remain stable due to consistent revenue growth and cost management.",
Financial snapshot
PeriodHA-latest
CurrencyEGP
Revenue$1.18B
Gross profit$435.6M
Operating income$276.3M
Net income$182.2M
R&D
SG&A
D&A
SBC
Operating cash flow$373.6M
CapEx-$755.8M
Free cash flow-$501.7M
Total assets$5.24B
Total liabilities$2.80B
Total equity$2.44B
Cash & equivalents$28.6M
Long-term debt$1.23B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$2.55B$509.5M$387.2M$237.2M
FY-3$2.61B$444.1M$325.8M$25.3M
FY-2$3.60B$650.8M$418.2M-$236.2M
FY-1$5.42B$1.16B$723.3M-$1.76B
FY0$7.23B$1.49B$823.9M-$1.58B
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$3.43B$2.38B$15.0M
FY-3$3.28B$1.88B$21.2M
FY-2$4.49B$2.25B$6.7M
FY-1$7.59B$2.90B$145.8M
FY0$10.24B$3.62B$89.5M
PeriodOCFCapExFCFSBC
FY-4$648.2M-$282.2M$237.2M
FY-3$436.0M-$424.7M$25.3M
FY-2$558.0M-$825.2M-$236.2M
FY-1$1.50B-$2.70B-$1.76B
FY0$1.89B-$2.65B-$1.58B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$1.18B$276.3M$182.2M-$501.7M
FQ-6$1.19B$230.5M$143.0M$2.8M
FQ-5$1.46B$333.0M$207.2M-$819.7M
FQ-4$1.59B$322.9M$190.9M-$331.1M
FQ-3$1.62B$348.4M$200.6M-$346.7M
FQ-2$1.76B$432.3M$250.4M-$266.4M
FQ-1$1.94B$471.1M$269.0M-$339.9M
FQ0$1.91B$237.9M$103.9M-$476.9M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$5.24B$2.44B$28.6M
FQ-6$5.68B$2.50B$10.0M
FQ-5$6.84B$2.69B$58.2M
FQ-4$7.59B$2.90B$145.8M
FQ-3$8.78B$3.13B$178.5M
FQ-2$9.21B$3.27B$52.0M
FQ-1$9.98B$3.52B$89.1M
FQ0$10.24B$3.62B$89.5M
PeriodOCFCapExFCFSBC
FQ-7$373.6M-$755.8M-$501.7M
FQ-6$288.9M-$967.5M$2.8M
FQ-5$1.11B-$2.08B-$819.7M
FQ-4$1.50B-$2.70B-$331.1M
FQ-3$532.5M-$638.3M-$346.7M
FQ-2$682.0M-$1.26B-$266.4M
FQ-1$1.70B-$1.98B-$339.9M
FQ0$1.89B-$2.65B-$476.9M
Valuation
Market price$6.61
Market cap$9.58B
Enterprise value$10.78B
P/E52.6
Reported non-GAAP P/E
EV/Revenue9.1
EV/Op income39.0
EV/OCF28.9
P/B3.9
P/Tangible book3.9
Tangible book$2.44B
Net cash-$1.20B
Current ratio1.4
Debt/Equity0.5
ROA3.5%
ROE7.5%
Cash conversion2.0%
CapEx/Revenue-64.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricCLHOActivity
Op margin23.4%7.7% medp25 -2.4% · p75 15.5%top quartile
Net margin15.4%5.9% medp25 -3.8% · p75 12.8%top quartile
Gross margin36.9%45.5% medp25 31.1% · p75 62.9%below median
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-64.0%-7.0% medp25 -14.9% · p75 -3.2%bottom quartile
Debt / equity50.0%25.0% medp25 3.8% · p75 63.3%above median
Observations
IR observations
Mean price target14.53 EGP
Median price target14.35 EGP
High price target17.50 EGP
Low price target11.90 EGP
Mean recommendation2.25 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count1.00
Hold count2.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.49 EGP
Last actual EPS0.46 EGP
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 02:53 UTC#51c432ae
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 15:57 UTCJob: 291f6a4f